Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG)

Autoimmunity

Volumn 39, Issue 8, 2006, Pages 711-717

  Molina, Vered ^a   Haj Yahia, Saleem ^a,b   Solodeev, Inna ^a   Levy, Yair ^a   Blank, Miri ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Animal model; Collagen I; IVIG; Pulmonary fibrosis; TGF 1

Indexed keywords

BLEOMYCIN; COLLAGEN TYPE 1; HYDROXYPROLINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PHOSPHATE BUFFERED SALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL MODEL; IMMUNOMODULATION; LUNG FIBROSIS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; STAINING; TISSUE SECTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; COLLAGEN TYPE I; HYDROXYPROLINE; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS;

EID: 33845712015     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930601061272     Document Type: Article

References (46)

1. Gross, TJ and Hunninghake, GW. (2001) Idiopathic pulmonary fibrosis N Engl J Med, 345(7), pp. 517-525.
2. Ong, CJ and Ip, S and Teh, SJ and (1999) A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice Cell Immunol, 196(1), pp. 60-68.
3. Fertin, C and Nicolas, JF and Gillery, P and Kalis, B and Banchereau, J and Maquart, FX. (1991) Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents Cell Mol Biol, 37(8), pp. 823-829.
4. Gillery, P and Fertin, C and Nicolas, JF and (1992) Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis FEBS Lett, 302(3), pp. 231-234.
5. Sempowski, GD and Beckmann, MP and Derdak, S and Phipps, RP. (1994) Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis J Immunol, 152(7), pp. 3606-3614.
6. Pablos, JL and Everett, ET and Harley, R and LeRoy, EC and Norris, JS. (1995) Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse Lab Invest, 72(6), pp. 670-678.
7. Peltonen, J and Kahari, L and Jaakkola, S and (1990) Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization J Invest Dermatol, 94(3), pp. 365-371.
8. Broekelmann, TJ and Limper, AH and Colby, TV and McDonald, JA. (1991) Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis Proc Natl Acad Sci U S A, 88(15), pp. 6642-6646.
9. McCormick, LL and Zhang, Y and Tootell, E and Gilliam, AC. (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma J Immunol, 163(10), pp. 5693-5699.
10. Ong, C and Wong, C and Roberts, CR and Teh, HS and Jirik, FR. (1998) Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma Eur J Immunol, 28(9), pp. 2619-2629.
11. Ryu, JH and Colby, TV and Hartman, TE. (1998) Idiopathic pulmonary fibrosis: Current concepts Mayo Clin Proc, 73(11), pp. 1085-1101.
12. Kolb, M and Margetts, PJ and Sime, PJ and Gauldie, J. (2001) Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung Am J Physiol Lung Cell Mol Physiol, 280(6), pp. L1327-L1334.
13. Pittet, JF and Griffiths, MJ and Geiser, T and (2001) TGF-beta is a critical mediator of acute lung injury J Clin Invest, 107(12), pp. 1537-1544.
14. Schirner, M and Hoffmann, J and Menrad, A and Schneider, MR. (1998) Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models Clin Cancer Res, 4(5), pp. 1331-1336.
15. Sausville, EA and Peisach, J and Horwitz, SB. (1978) Effect of chelating agents and metal ions on the degradation of DNA by bleomycin Biochemistry, 17(14), pp. 2740-2746.
16. Sausville, EA and Stein, RW and Peisach, J and Horwitz, SB. (1978) Properties and products of the degradation of DNA by bleomycin and iron(II) Biochemistry, 17(14), pp. 2746-2754.
17. Burger, RM and Peisach, J and Horwitz, SB. (1981) Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA J Biol Chem, 256(22), pp. 11636-11644.
18. Umezawa, H and Takeuchi, T and Hori, S and Sawa, T and Ishizuka, M. (1972) Studies on the mechanism of antitumor effect of bleomycin of squamous cell carcinoma J Antibiot (Tokyo) 25(7), pp. 409-420.
19. Onuma, T and Holland, JF and Masuda, H and Waligunda, JA and Goldberg, GA. (1974) Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance Cancer, 33(5), pp. 1230-1238.
20. Snider, GL and Hayes, JA and Korthy, AL. (1978) Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: Pathology and stereology Am Rev Respir Dis, 117(6), pp. 1099-1108.
21. Bayry, J and Thirion, M and Misra, N and (2003) Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases Neurol Sci, 24(Suppl 4), pp. S217-S221.
22. Levy, Y and Sherer, Y and Langevitz, P and (2000) Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report Clin Rheumatol, 19(3), pp. 207-211.
23. Lister, RK and Jolles, S and Whittaker, S and (2000) Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg) J Am Acad Dermatol, 43(2 Pt 2), pp. 403-408.
24. Levy, Y and Amital, H and Langevitz, P and (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study Arthritis Rheum, 50(3), pp. 1005-1007.
25. Campbell, DE and Georgiou, GM and Kemp, AS. (1999) Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen Cytokine, 11(5), pp. 359-365.
26. Amemiya, K and Semino-Mora, C and Granger, RP and Dalakas, MC. (2000) Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin Clin Immunol, 94(2), pp. 99-104.
27. Blank, M and Levy, Y and Amital, H and Shoenfeld, Y and Pines, M and Genina, O. (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice Arthritis Rheum, 46(6), pp. 1689-1690.
28. Mollnes, TE and Andreassen, IH and Hogasen, K and Hack, CE and Harboe, M. (1997) Effect of whole and fractionated intravenous immunoglobulin on complement in vitro Mol Immunol, 34(10), pp. 719-729.
29. Lutz, HU and Stammler, P and Bianchi, V and (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level Blood, 103(2), pp. 465-472.
30. Grande, JP. (1997) Role of transforming growth factor-beta in tissue injury and repair Proc Soc Exp Biol Med, 214(1), pp. 27-40.
31. Andersson, J and Skansen-Saphir, U and Sparrelid, E and Andersson, U. (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages Clin Exp Immunol, 104(Suppl 1), pp. 10-20.
32. Shapiro, S and Shoenfeld, Y and Gilburd, B and Sobel, E and Lahat, N. (2002) Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages Cancer, 95(9), pp. 2032-2037.
33. Sherer, Y and Levy, Y and Langevitz, P and Rauova, L and Fabrizzi, F and Shoenfeld, Y. (2001) Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases Pharmacology, 62(3), pp. 133-137.
34. Kaminski, N and Allard, JD and Pittet, JF and (2000) Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis Proc Natl Acad Sci U S A, 97(4), pp. 1778-1783.
35. Zuo, F and Kaminski, N and Eugui, E and (2002) Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans Proc Natl Acad Sci U S A, 99(9), pp. 6292-6297.
36. Ortiz, LA and Gambelli, F and McBride, C and (2003) Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects Proc Natl Acad Sci U S A, 100(14), pp. 8407-8411.
37. Izbicki, G and Segel, MJ and Christensen, TG and Conner, MW and Breuer, R. (2002) Time course of bleomycin-induced lung fibrosis Int J Exp Pathol, 83(3), pp. 111-119.
38. Bayry, J and Lacroix-Desmazes, S and Delignat, S and (2003) Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus Arthritis Rheum, 48(12), pp. 3497-3502.
39. Mullbacher, A and Lobigs, M and Hla, RT and Tran, T and Stehle, T and Simon, MM. (2002) Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis J Immunol, 169(1), pp. 145-150.
40. Ahn, JH and Park, SM and Cho, HS and (2001) Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression J Biol Chem, 276(50), pp. 47100-47106.
41. Prasad, NK and Papoff, G and Zeuner, A and (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway J Immunol, 161(7), pp. 3781-3790.
42. Ronda, N and Gatti, R and Giacosa, R and (2002) Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway Arthritis Rheum, 46(6), pp. 1595-1601.
43. Ronda, N and Raschi, E and Testoni, C and (2002) Anti-fibroblast antibodies in systemic sclerosis Isr Med Assoc J, 4(11), pp. 858-864.
44. Shoenfeld, Y and Krause, I. (2004) i.v. IG for autoimmune, fibrosis, and malignant conditions: Our experience with 200 patients J Clin Immunol, 24(2), pp. 107-114.
45. Amital, H and Rewald, E and Levy, Y and (2003) Fibrosis regression induced by intravenous gammaglobulin treatment Ann Rheum Dis, 62(2), pp. 175-177.
46. Aharon, A and Levy, Y and Bar-Dayan, Y and (1997) Successful treatment of early secondary myelofibrosis in SLE with IVIG Lupus, 6(4), pp. 408-411.